National Cancer Institute. Cancer stat facts: NHL: follicular lymphoma. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed 2 Mar 2023.

Hanel W, Epperla N. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol. 2021;14:104. https://doi.org/10.1186/s13045-021-01113-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103. https://doi.org/10.1016/S1470-2045(21)00591-X.

Article  CAS  PubMed  Google Scholar 

Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019;133:1540–7. https://doi.org/10.1182/blood-2018-08-822148.

Article  CAS  PubMed  Google Scholar 

Alcoceba M, Alonso-Álvarez S, García-Álvarez M, et al. Unmet needs in histological transformation of follicular lymphoma: a clinical and biological review. Ann Lymphoma. 2017;1:11. https://doi.org/10.21037/aol.2017.11.03.

Article  Google Scholar 

Prusila REI, Sorigue M, Jauhiainen J, et al. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. Br J Haematol. 2019;187:364–71. https://doi.org/10.1111/bjh.16090.

Article  CAS  PubMed  Google Scholar 

Bello C, Zhang L, Naghashpour M. Follicular lymphoma: current management and future directions. Cancer Control. 2012;19:187–95. https://doi.org/10.1177/107327481201900303.

Article  PubMed  Google Scholar 

Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study. J Clin Oncol. 2015;33:2516–22. https://doi.org/10.1200/JCO.2014.59.7534.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare study. Br J Haematol. 2019;184:660–3. https://doi.org/10.1111/bjh.15149.

Article  PubMed  Google Scholar 

NCCN. Clinical practice guidelines in oncology (NCCN Guidelines®) for B-cell lymphomas. V2.2023. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 2 Mar 2023.

Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines Consensus Conference on Malignant Lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561–76. https://doi.org/10.1093/annonc/mds517.

Mozas P, Nadeu F, Rivas-Delgado A, et al. Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer J. 2020;10:31. https://doi.org/10.1038/s41408-020-0299-0.

Article  PubMed  PubMed Central  Google Scholar 

Morrison VA, Shou Y, Bell JA, et al. Treatment patterns and survival outcomes in patients with follicular lymphoma: a 2007 to 2015 Humedica Database study. Clin Lymphoma Myeloma Leuk. 2019;19:e172–83. https://doi.org/10.1016/j.clml.2018.12.017.

Article  PubMed  Google Scholar 

Rivas-Delgado A, Magnano L, Moreno-Velazquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019;184:753–9. https://doi.org/10.1111/bjh.15708.

Article  CAS  PubMed  Google Scholar 

Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37:1188–99. https://doi.org/10.1200/jco.19.00010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Revlimid® (lenalidomide) [package insert]. Summit (NJ): Celgene Corporation; 2019.

Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137–43. https://doi.org/10.1182/blood-2013-01-481341.

Article  CAS  PubMed  Google Scholar 

Gazyva® (obinutuzumab) [package insert]. South San Francisco (CA): Genentech, Inc.; 2022.

Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36:2259–66. https://doi.org/10.1200/jco.2017.76.3656.

Article  CAS  PubMed  Google Scholar 

Sehn LH, Hübel K, Luminari S, et al. inMIND: a phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma. J Clin Oncol. 2022;40:Abstract TPS7583. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS7583.

Clinicaltrials.gov. A phase 3 study to assess efficacy and safety of tafasitamab plus lenalidomide and rituximab compared to placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma or marginal zone lymphoma (InMIND). Updated 2 Dec 2022. https://clinicaltrials.gov/ct2/show/NCT04680052. Accessed 2 Mar 2023.

Monjuvi® (tafasitamab-cxix) [package insert]. Boston (MA): MORPHOSYS US INC.; 2020.

Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433–42. https://doi.org/10.1016/S1470-2045(20)30441-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tazverik™ (tazemetostat) [package insert]. Cambridge: Epizyme, Inc.; 2020.

Andorsky DJ, Coleman M, Yacoub A, et al. MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL. J Clin Oncol. 2020;38:Abstract 8046. https://doi.org/10.1200/JCO.2020.38.15_suppl.8046.

Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6:e429–37. https://doi.org/10.1016/s2352-3026(19)30089-4.

Article  PubMed  Google Scholar 

Zelenetz AD, Jurczak W, Ribrag V, et al. Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the global phase 2 study TIDAL. J Clin Oncol. 2022;40:Abstract 7511. https://doi.org/10.1200/JCO.2022.40.16_suppl.7511.

ClinicalTrials.gov. Phase 3 study of zandelisib (ME-401) in combination with rituximab in patients with iNHL - (COASTAL). Updated 13 Jan 2023. https://clinicaltrials.gov/ct2/show/NCT04745832. Accessed 2 Mar 2023.

ClinicalTrials.gov. Zandelisib (ME-401) in subjects with follicular lymphoma or marginal zone lymphoma after failure of two or more prior therapies (TIDAL). Updated 13 Jan 2023. https://clinicaltrials.gov/ct2/show/NCT03768505. Accessed 2 Mar 2023.

Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol. 2018;36:2405–12. https://doi.org/10.1200/jco.2017.76.8853.

Article  CAS  PubMed  Google Scholar 

Zinzani PL, Mayer J, Flowers CR, et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol. 2023;41(33):5107–17. https://doi.org/10.1200/JCO.23.00775.

Article  CAS  PubMed  Google Scholar 

Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021;137:637–45. https://doi.org/10.1182/blood.2019004753.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding W, Laplant B, Witzig TE, et al. PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma. Blood. 2017;130:Abstract 4055. https://doi.org/10.1182/blood.V130.Suppl_1.4055.4055.

Sehn LH, Kamdar M, Herrera AF, et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. J Clin Oncol. 2018;36:Abstract 7507. https://doi.org/10.1200/JCO.2018.36.15_suppl.7507.

Brukinsa® (zanubrutinib) [package insert]. Cambridge (MA): BeiGene, Ltd; 2024.

Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055–65. https://doi.org/10.1016/s1470-2045(22)00335-7.

Article  CAS  PubMed  Google Scholar 

Lunsumio (mosunetuzumab) [package insert]. South San Francisco (CA): Genentech, Inc.; 2022.

Yescarta® (axicabtagene ciloleucel) [package insert]. Santa Monica (CA): Kite Pharma, Inc.; 2022.

Yescarta (axicabtagene ciloleucel) [summary of product characteristics]. Hoofddorp: Kite Pharma EU B.V.; 2022.

Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325–32. https://doi.org/10.1038/s41591-021-01622-0.

Article  CAS  PubMed  Google Scholar 

Kymriah® (tisagenlecleucel) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2022.

Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34:1104–11. https://doi.org/10.1200/jco.2014.59.1586.

Article  CAS  PubMed  Google Scholar 

Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39:1959–70. https://doi.org/10.1200/jco.20.03175.

Article  CAS